SG11202103133QA - Pyrazole derivatives as h4 antagonist compounds - Google Patents
Pyrazole derivatives as h4 antagonist compoundsInfo
- Publication number
- SG11202103133QA SG11202103133QA SG11202103133QA SG11202103133QA SG11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA SG 11202103133Q A SG11202103133Q A SG 11202103133QA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazole derivatives
- antagonist compounds
- antagonist
- compounds
- pyrazole
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003396 histamine H4 receptor antagonist Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1817047.2A GB201817047D0 (en) | 2018-10-19 | 2018-10-19 | H4 antagonist compounds |
PCT/GB2019/052997 WO2020079457A1 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103133QA true SG11202103133QA (en) | 2021-05-28 |
Family
ID=64453795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103133QA SG11202103133QA (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
Country Status (12)
Country | Link |
---|---|
US (2) | US12234227B2 (en) |
EP (1) | EP3867248A1 (en) |
JP (1) | JP7532353B2 (en) |
KR (1) | KR20210079318A (en) |
CN (1) | CN113272297B (en) |
AU (1) | AU2019360428B2 (en) |
BR (1) | BR112021007372A2 (en) |
CA (1) | CA3116628A1 (en) |
GB (1) | GB201817047D0 (en) |
MX (1) | MX2021004280A (en) |
SG (1) | SG11202103133QA (en) |
WO (1) | WO2020079457A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202005858D0 (en) * | 2020-04-22 | 2020-06-03 | Heptares Therapeutics Ltd | H4 Antagonist compounds |
GB202019667D0 (en) * | 2020-12-14 | 2021-01-27 | Heptares Therapeutics Ltd | H4 antagonist comnpounds |
WO2022203399A1 (en) * | 2021-03-26 | 2022-09-29 | 주식회사 스탠다임 | Adenosine a2a receptor antagonist and use thereof |
EP4421067A1 (en) * | 2021-10-19 | 2024-08-28 | Unimatec Co., Ltd. | Fluorine-containing pyrazole compound and production method therefor |
KR102621694B1 (en) * | 2022-09-15 | 2024-01-08 | 주식회사 스탠다임 | Adenosine a2a receptor antagonist and use thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4800299A (en) * | 1998-07-24 | 2000-02-14 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives and salts thereof |
JP2000169475A (en) | 1998-07-24 | 2000-06-20 | Dai Ichi Seiyaku Co Ltd | Pyrazole derivative and salt thereof |
WO2005054239A1 (en) * | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
NL2000323C2 (en) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine derivatives. |
US20100035863A1 (en) | 2006-09-12 | 2010-02-11 | Ucb Pharma, S.A. | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions |
US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
CL2008000467A1 (en) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | COMPOUNDS DERIVED FROM 2-AMINOPIRIMIDINE, HISTAMINE RECEIVER MODULATORS H4; YOUR PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT A SELECTED INFLAMMATORY DISORDER OF ALEGIA, ASMA |
WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
PE20091524A1 (en) | 2007-12-19 | 2009-09-25 | Palau Pharma Sa | DERIVATIVES OF 2-AMINOPYRIMIDINE |
SI2235012T1 (en) | 2007-12-21 | 2013-11-29 | Palau Pharma, S.A. | 4-aminopyrimidine derivatives as histamine h4 receptor antagonists |
JP5743897B2 (en) * | 2008-11-20 | 2015-07-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Compound |
TW201035078A (en) | 2009-03-20 | 2010-10-01 | Incyte Corp | Substituted heterocyclic compounds |
KR20120092141A (en) | 2009-10-29 | 2012-08-20 | 서트리스 파마슈티컬즈, 인코포레이티드 | Bicyclic pyridines and analogs as sirtuin modulators |
RU2573828C2 (en) | 2009-12-23 | 2016-01-27 | Медисиз Фармасьютикал Корпорейшн | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
ES2620119T3 (en) | 2012-11-16 | 2017-06-27 | Merck Patent Gmbh | Novel heterocyclic derivatives as modulators of kinase activity |
WO2018023029A1 (en) | 2016-07-28 | 2018-02-01 | Mayo Foundation For Medical Education And Research | Small molecule activators of parkin enzyme function |
-
2018
- 2018-10-19 GB GBGB1817047.2A patent/GB201817047D0/en not_active Ceased
-
2019
- 2019-10-21 MX MX2021004280A patent/MX2021004280A/en unknown
- 2019-10-21 AU AU2019360428A patent/AU2019360428B2/en active Active
- 2019-10-21 WO PCT/GB2019/052997 patent/WO2020079457A1/en active IP Right Grant
- 2019-10-21 CN CN201980084053.7A patent/CN113272297B/en active Active
- 2019-10-21 EP EP19794235.2A patent/EP3867248A1/en active Pending
- 2019-10-21 JP JP2021521390A patent/JP7532353B2/en active Active
- 2019-10-21 BR BR112021007372-8A patent/BR112021007372A2/en unknown
- 2019-10-21 KR KR1020217014805A patent/KR20210079318A/en active Pending
- 2019-10-21 CA CA3116628A patent/CA3116628A1/en active Pending
- 2019-10-21 US US17/285,776 patent/US12234227B2/en active Active
- 2019-10-21 SG SG11202103133QA patent/SG11202103133QA/en unknown
-
2024
- 2024-09-05 US US18/826,098 patent/US20250115587A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3867248A1 (en) | 2021-08-25 |
JP2022507013A (en) | 2022-01-18 |
US20250115587A1 (en) | 2025-04-10 |
US12234227B2 (en) | 2025-02-25 |
GB201817047D0 (en) | 2018-12-05 |
US20210300906A1 (en) | 2021-09-30 |
CN113272297A (en) | 2021-08-17 |
KR20210079318A (en) | 2021-06-29 |
CN113272297B (en) | 2024-03-19 |
AU2019360428B2 (en) | 2024-05-09 |
JP7532353B2 (en) | 2024-08-13 |
MX2021004280A (en) | 2021-05-31 |
AU2019360428A1 (en) | 2021-04-29 |
WO2020079457A1 (en) | 2020-04-23 |
CA3116628A1 (en) | 2020-04-23 |
BR112021007372A2 (en) | 2021-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272056A (en) | Heterocyclic compounds as adenosine antagonists | |
ZA202204675B (en) | New methylquinazolinone derivatives | |
SG11202103133QA (en) | Pyrazole derivatives as h4 antagonist compounds | |
IL279452B (en) | Pyrazole derivatives as malt1 inhibitors | |
IL279453B (en) | Pyrazole derivatives as malt1 inhibitors | |
IL289197A (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
IL283990A (en) | Substituted oxopyridine derivatives | |
IL284767A (en) | Heterocyclic compounds as adenosine antagonists | |
EP3331532A4 (en) | Substituted aminoquinazoline compounds as a2a antagonist | |
ZA201708611B (en) | Pyrazole derivative, or pharmaceutically acceptable salt thereof | |
PL4077334T3 (en) | Furoindazole derivatives | |
IL290815A (en) | Alpha-d-galactopyranoside derivatives | |
IL279938A (en) | Spirochromane derivatives | |
IL284762A (en) | Heterocyclic compounds as adenosine antagonists | |
LT3796975T (en) | Sulfonylaminobenzamide derivatives | |
IL310777A (en) | Substituted s-alaninate derivatives | |
GB201919213D0 (en) | Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds | |
GB201919210D0 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
ZA201904313B (en) | Heterocyclic derivatives as antibacterial compounds | |
HUE062256T2 (en) | Dihydrochromene derivatives | |
HK40048587A (en) | Pyrazole derivatives as h4 antagonist compounds | |
GB201918392D0 (en) | H4 Antagonist compounds | |
ZA202200181B (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
GB201901868D0 (en) | H4 antagonist compounds | |
HK40029095A (en) | Heterocyclic compounds as adenosine antagonists |